Syncom Formulations (India) Share Price & Earnings Call Analysis

₹19.07-0.68% today

Market cap: ₹1,793 Cr
P/E: 21.13
ROE: 17.60%
PEG: 0.43
Price to sales: 3.63
Debt to equity: 0.00
52W high / low: ₹26.2 / ₹10.3
Sales growth (5Y): 14.69%
EBITDA margin: 17.64%
Net profit margin: 13.63%
Promoter holding: 50.57%
Sales (last year): ₹495 Cr

All 12 ratios ↓

Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

See all potential multibaggers Where does Syncom Formulations (India) rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

1. Pick 3–15 stocks
2. Choose large, mid or small cap and your sectors
3. Get a portfolio built from the rankings

Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#	Company	Revenue guided	Margin guided	Market cap	P/E
1		40%+	Up 2%+	₹480 Cr	19.1
2		40%+	Up 0–2%	₹212 Cr	16.1
3		40%+	Flat	₹17,925 Cr	—
4		40%+	Flat	₹5,223 Cr	39.1
5		40%+	Flat	₹4,268 Cr	—
6		40%+	Flat	₹40 Cr	—

Sign up free to see every company in the sector ranking and track Syncom Formulations (India).

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Syncom Formulations (India)

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Syncom Formulations (India)

Quarterly Results

Quarter-by-quarter operating performance

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	61	59	62	63	73	87	101	127	148	117	121	115	134
Expenses +	55	53	56	57	64	76	90	112	131	101	103	93	113
Operating Profit	6	6	6	7	9	10	12	15	17	16	19	21	21
OPM %	10%	10%	10%	11%	12%	12%	12%	11%	12%	14%	15%	18%	16%
Other Income +	7	2	4	4	3	1	4	4	7	6	5	5	14
Interest	1	1	1	1	1	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1	1	1	2
Profit before tax	10	6	8	9	9	10	15	17	23	20	22	25	33
Tax %	18%	27%	24%	25%	27%	24%	25%	24%	24%	22%	25%	25%	25%
Net Profit +	8	4	6	6	7	8	11	13	18	16	17	19	25
EPS in Rs	0.09	0.05	0.07	0.07	0.07	0.08	0.12	0.14	0.19	0.17	0.18	0.20	0.26

Financials of Syncom Formulations (India)

Profit & Loss

Annual income statement trend

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales +	173	184	185	159	187	206	245	216	222	257	461	487
Expenses +	155	167	168	147	175	189	207	196	202	229	407	409
Operating Profit	18	17	16	12	12	17	38	20	20	28	54	77
OPM %	11%	9%	9%	7%	6%	8%	16%	9%	9%	11%	12%	16%
Other Income +	1	3	3	4	5	5	7	12	15	13	17	31
Interest	0	0	0	0	0	1	0	2	3	5	1	1
Depreciation	3	3	3	4	4	4	4	4	5	5	5	7
Profit before tax	16	16	16	12	13	17	41	26	27	32	65	101
Tax %	38%	36%	33%	28%	12%	18%	28%	24%	24%	26%	24%	24%
Net Profit +	10	10	11	9	11	14	29	20	20	24	49	76
EPS in Rs	0.13	0.13	0.14	0.11	0.14	0.18	0.37	0.23	0.21	0.25	0.52	0.81
Dividend Payout %	16%	15%	15%	0%	0%	0%	0%	13%	0%	0%	0%	0%

Financials of Syncom Formulations (India)

Balance Sheet

Capital structure and asset base

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	78	78	78	78	78	78	79	86	94	94	94	94
Reserves	22	31	36	44	55	68	109	136	162	192	246	318
Borrowings +	6	6	12	12	9	2	62	58	83	72	4	1
Other Liabilities +	31	61	48	37	32	33	42	28	38	33	66	116
Total Liabilities	138	175	175	171	173	181	292	308	377	392	410	529
Fixed Assets +	46	46	85	89	89	93	91	94	91	120	125	184
CWIP	0	5	0	1	0	0	0	6	26	0	0	0
Investments	6	23	1	2	2	1	11	43	64	66	93	109
Other Assets +	85	101	89	79	83	87	189	165	196	206	192	237
Total Assets	138	175	175	171	173	181	292	308	377	392	410	529

Financials of Syncom Formulations (India)

Cash Flows

Operating, investing and financing cash movement

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	0	24	17	-2	4	6	-2	16	10	-6	23	58
Cash from Investing Activity +	1	-23	-8	-2	2	2	-75	-27	-45	84	-18	-51
Cash from Financing Activity +	1	-2	-2	-2	-0	-7	72	8	35	-15	-68	-3
Net Cash Flow	2	-1	6	-6	7	1	-5	-2	1	63	-63	4
Free Cash Flow	-3	16	9	-8	10	4	-5	5	-10	-14	13	47
CFO/OP	32%	176%	128%	13%	66%	61%	24%	113%	86%	6%	70%	105%

Financials of Syncom Formulations (India)

Ratios

Working capital efficiency and return ratios

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	66	91	91	87	81	77	112	114	124	132	85	81
Inventory Days	34	43	29	37	37	39	51	51	53	49	49	81
Days Payable	63	130	92	75	57	49	66	36	52	33	51	96
Cash Conversion Cycle	37	4	27	49	61	67	96	129	124	148	83	66
Working Capital Days	84	40	45	75	74	88	28	33	-4	51	95	164
ROCE %	16%	15%	14%	9%	9%	12%	21%	11%	10%	10%	19%	27%

Momentum score · price trend

41 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

Period	Share price change	Better than … of 1,910 stocks
Last 12 months	+16.8%	72%
Last 6 months	+39.2%	86%
Last 3 months	+45.6%	97%

The price is 26.7% below its all-time high of ₹26.18 (29 Sept 2026). Stocks more than 20% below their peak have their score halved, so 83 became 41.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Syncom Formulations (India): 0.4 × 72 + 0.4 × 86 + 0.2 × 97 = 83, halved to 41 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Others in Pharmaceuticals & Biotechnology this season

Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industries vs Divis Laboratories vs Torrent Pharmaceuticals